568 related articles for article (PubMed ID: 25994967)
1. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
[TBL] [Abstract][Full Text] [Related]
2. Third-party regulatory T cells prevent murine acute graft-versus-host disease.
Lim JY; Im KI; Song Y; Kim N; Nam YS; Jeon YW; Cho SG
Korean J Intern Med; 2018 Sep; 33(5):980-989. PubMed ID: 29050459
[TBL] [Abstract][Full Text] [Related]
3. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.
Pillai AB; George TI; Dutt S; Strober S
Blood; 2009 Apr; 113(18):4458-67. PubMed ID: 19221040
[TBL] [Abstract][Full Text] [Related]
4. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of graft-versus-host disease by double-negative regulatory T cells.
Young KJ; DuTemple B; Phillips MJ; Zhang L
J Immunol; 2003 Jul; 171(1):134-41. PubMed ID: 12816991
[TBL] [Abstract][Full Text] [Related]
6. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model.
Yang J; Fan H; Hao J; Ren Y; Chen L; Li G; Xie R; Yang Y; Qian K; Liu M
Transfusion; 2012 Jun; 52(6):1333-47. PubMed ID: 22098312
[TBL] [Abstract][Full Text] [Related]
7. Adoptive transfusion of ex vivo donor alloantigen-stimulated CD4(+)CD25(+) regulatory T cells ameliorates rejection of DA-to-Lewis rat liver transplantation.
Pu LY; Wang XH; Zhang F; Li XC; Yao AH; Yu Y; Lv L; Li GQ
Surgery; 2007 Jul; 142(1):67-73. PubMed ID: 17630002
[TBL] [Abstract][Full Text] [Related]
8. Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality.
Schneidawind D; Baker J; Pierini A; Buechele C; Luong RH; Meyer EH; Negrin RS
Blood; 2015 May; 125(22):3491-500. PubMed ID: 25795920
[TBL] [Abstract][Full Text] [Related]
9. IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.
Koenecke C; Lee CW; Thamm K; Föhse L; Schafferus M; Mittrücker HW; Floess S; Huehn J; Ganser A; Förster R; Prinz I
J Immunol; 2012 Sep; 189(6):2890-6. PubMed ID: 22869903
[TBL] [Abstract][Full Text] [Related]
10. HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease.
Li J; Heinrichs J; Haarberg K; Semple K; Veerapathran A; Liu C; Anasetti C; Yu XZ
J Immunol; 2015 Jul; 195(2):717-25. PubMed ID: 26048147
[TBL] [Abstract][Full Text] [Related]
11. CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells.
Schneidawind D; Pierini A; Alvarez M; Pan Y; Baker J; Buechele C; Luong RH; Meyer EH; Negrin RS
Blood; 2014 Nov; 124(22):3320-8. PubMed ID: 25293774
[TBL] [Abstract][Full Text] [Related]
12. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
13. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
14. TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment.
Pierini A; Strober W; Moffett C; Baker J; Nishikii H; Alvarez M; Pan Y; Schneidawind D; Meyer E; Negrin RS
Blood; 2016 Aug; 128(6):866-71. PubMed ID: 27365424
[TBL] [Abstract][Full Text] [Related]
15. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].
Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372
[TBL] [Abstract][Full Text] [Related]
16. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
[TBL] [Abstract][Full Text] [Related]
17. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.
Parmar S; Liu X; Tung SS; Robinson SN; Rodriguez G; Cooper LJ; Yang H; Shah N; Yang H; Konopleva M; Molldrem JJ; Garcia-Manero G; Najjar A; Yvon E; McNiece I; Rezvani K; Savoldo B; Bollard CM; Shpall EJ
Cytotherapy; 2014 Jan; 16(1):90-100. PubMed ID: 24480547
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease.
Theil A; Tuve S; Oelschlägel U; Maiwald A; Döhler D; Oßmann D; Zenkel A; Wilhelm C; Middeke JM; Shayegi N; Trautmann-Grill K; von Bonin M; Platzbecker U; Ehninger G; Bonifacio E; Bornhäuser M
Cytotherapy; 2015 Apr; 17(4):473-86. PubMed ID: 25573333
[TBL] [Abstract][Full Text] [Related]
19. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD.
Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX
Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018
[TBL] [Abstract][Full Text] [Related]
20. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
